Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Common Equity (2016 - 2025)

Historic Common Equity for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to $274.8 million.

  • Collegium Pharmaceutical's Common Equity rose 1729.95% to $274.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $274.8 million, marking a year-over-year increase of 1729.95%. This contributed to the annual value of $228.8 million for FY2024, which is 1709.61% up from last year.
  • Per Collegium Pharmaceutical's latest filing, its Common Equity stood at $274.8 million for Q3 2025, which was up 1729.95% from $232.2 million recorded in Q2 2025.
  • Collegium Pharmaceutical's 5-year Common Equity high stood at $274.8 million for Q3 2025, and its period low was $170.0 million during Q1 2021.
  • In the last 5 years, Collegium Pharmaceutical's Common Equity had a median value of $202.9 million in 2021 and averaged $213.7 million.
  • Its Common Equity has fluctuated over the past 5 years, first surged by 6246.45% in 2021, then crashed by 2191.29% in 2022.
  • Quarter analysis of 5 years shows Collegium Pharmaceutical's Common Equity stood at $202.9 million in 2021, then decreased by 3.98% to $194.8 million in 2022, then rose by 0.3% to $195.4 million in 2023, then rose by 17.1% to $228.8 million in 2024, then grew by 20.09% to $274.8 million in 2025.
  • Its Common Equity stands at $274.8 million for Q3 2025, versus $232.2 million for Q2 2025 and $234.4 million for Q1 2025.